Answers are grounded in this paper and cite their sources.
Background: This cross-sectional study characterized urinary Candida isolates and evaluated in-vitro itraconazole susceptibility using phenotypic and genotypic methods in a tertiary-care hospital. Methods: A total of 105 nonduplicate Candida isolates recovered from urine samples submitted for suspected UTI were identified by Gram staining, germ tube test, CHROMagar Candida , and sugar fermentation tests. Antifungal susceptibility to itraconazole and other azoles was assessed by Kirby–Bauer disk diffusion, and minimum inhibitory concentrations (MICs) were determined by microbroth dilution in accordance with CLSI guidelines. Real-time PCR targeting the ERG11 gene was performed to detect mutations associated with azole resistance. Results: Candida albicans was the most prevalent species (39%), followed by C. krusei, C. tropicalis, C. parapsilosis and C. glabrata . Itraconazole resistance was observed in 45.7% of isolates, with nonalbicans species contributing substantially to the resistant fraction. ERG11 mutations were detected in 40 itraconazole-resistant strains, showing strong correlation with phenotypic resistance profiles. Conclusion: The observed in-vitro itraconazole nonsusceptibility describes the sampled urinary isolates and does not establish itraconazole as a treatment option for Candida UTI or confirm infection in every culture-positive patient. These findings support diagnostic stewardship and more appropriate antifungal therapy in hospital and high-risk settings.
No takes yet. Share an insight, caveat, or question.
Fathima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: